The mechanisms of HCV eradication following IFN-?/ribavirin therapy in HCV/HIV-1 co-infection or HCV mono-infection remain unclear. The goal of this proposal is to determine the role of innate immunity effectors in therapy response in HCV and HCV/HIV-1 co-infected subjects by investigating Natural Killer (NK) cell and Dendritic Cell (DC) functionality in relation to level of adaptive T cell responses and therapy-induced HCV suppression. We will test the hypothesis that the sustained functional response of innate effector cells (i.e. Natural Killer cell and Dendritic cell function) to IFN-??/ribavirin therapy is a determinant of both innate and level of adaptive (HCV-specific) responses and ultimately early and sustained HCV virologic suppression. As a corollary, we hypothesize that innate phenotypes and cell-mediated responses associated with HCV control would be selectively enriched in subjects with documented SVS (independent of HIV-1 infection) as compared to healthy or HIV-1-infected donors without HCV infection. We will test this hypothesis by two aims on KIR/HLA-C typed HCV-infected and HCV/HIV-co-infected subjects undergoing treatment with peg-IFN- a/ribavirin by: (1) Analyzing a prospective longitudinal cohort of subjects reaching 12 wk EVR with follow-up to SVR, as compared to subjects failing to achieve EVR but remaining on therapy, with data collection for: (a) Levels of NK and DC subset distribution, DC maturation status and overall cellular immune activation by flow cytometry in relation to HCV viral load;(b) Degree of IRF-7 increase within PDC subsets as a reflection of IFN-a/STAT1/IRF-7 feedback loop and retained IFNR-I function, as measured by flow cytometry detection of IFN-a-induced STAT1 phosphorylation in PBMC subsets;(c) NK constitutive and IFN-a-induced lytic function against HLA-null or viral infected targets, including HCV-infected hepatocytes;and (d) Relation between innate functionality and levels of HCV T cell memory responses, as measured by IFN-? ELISPOT and tetramer assay at time of EVR and therapy completion. The second specific aim will analyze a cross-sectional cohort of previous mono-HCV or dual HCV/HIV-infected subjects having achieved HCV suppression and SVR status, as compared to uninfected controls, measuring (a) Flow-cytometric analysis of NK/DC subset frequency;(b) NK cell functional response (cytotoxicity and degranulation, STAT1 phosphorylation, expression of activation markers) to IFN-a, HLA-depleted target cells and HCV-infected hepatocyte;(c) Dendritic cell functional response (cytokine production, IRF-7 expression) to IFN-a and TLR ligands (CpG, Resiquimod). This basic and clinical research study represents a hypothesis-driven collaborative effort by the Wistar Institute, The Jonathan Lax Center for the Treatment of Immune Disorders (Philadelphia FIGHT), The Infectious Disease Division for the University of Pennsylvania, The AIDS clinic of Drexel University, The National Cancer Institute's Laboratory of Genomic Diversity and Laboratory of Experimental Immunology (Frederick, MD), BD Bioscience (San Diego CA), and the Department of Biostatistics of the University of Massachusetts-Amherst. Public Health Relevance Statement

Public Health Relevance

The mechanisms of HCV eradication following IFN-a/ribavirin therapy in HCV/HIV-1 co-infected or HCV mono-infected subjects remain unclear. The goal of this proposal is to determine the role of innate immunity effectors in IFN-a/ribavirin therapy response in HCV and HCV/HIV-1 co- infected subjects by investigating Natural Killer (NK) cell and Dendritic Cell (DC) functionality in relation to level of adaptive T cell responses and therapy-induced HCV viral suppression. As the rate of response to therapy varies from about 60% in mono-infection to <25% in HIV/HCV co-infected individuals, it is imperative that added research be conducted in understanding clearance mechanisms.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI073219-03
Application #
7920070
Study Section
AIDS Immunology and Pathogenesis Study Section (AIP)
Program Officer
Embry, Alan C
Project Start
2008-09-16
Project End
2012-08-31
Budget Start
2010-09-01
Budget End
2011-08-31
Support Year
3
Fiscal Year
2010
Total Cost
$792,714
Indirect Cost
Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Papasavvas, Emmanouil; Lada, Steven M; Joseph, Jocelin et al. (2018) Analytical ART interruption does not irreversibly change pre-interruption levels of cellular HIV. AIDS :
Papasavvas, E; Azzoni, L; Yin, X et al. (2017) HCV viraemia associates with NK cell activation and dysfunction in antiretroviral therapy-treated HIV/HCV-co-infected subjects. J Viral Hepat 24:865-876
Patro, Sean C; Azzoni, Livio; Joseph, Jocelin et al. (2016) Antiretroviral therapy in HIV-1-infected individuals with CD4 count below 100 cells/mm3 results in differential recovery of monocyte activation. J Leukoc Biol 100:223-31
Tomescu, Costin; Seaton, Kelly E; Smith, Peter et al. (2015) Innate activation of MDC and NK cells in high-risk HIV-1-exposed seronegative IV-drug users who share needles when compared with low-risk nonsharing IV-drug user controls. J Acquir Immune Defic Syndr 68:264-73
Papasavvas, Emmanouil; Foulkes, Andrea; Yin, Xiangfan et al. (2015) Plasmacytoid dendritic cell and functional HIV Gag p55-specific T cells before treatment interruption can inform set-point plasma HIV viral load after treatment interruption in chronically suppressed HIV-1(+) patients. Immunology 145:380-90
Patro, Sean C; Pal, Sharmistha; Bi, Yingtao et al. (2015) Shift in monocyte apoptosis with increasing viral load and change in apoptosis-related ISG/Bcl2 family gene expression in chronically HIV-1-infected subjects. J Virol 89:799-810
Tomescu, Costin; Liu, Qin; Ross, Brian N et al. (2014) A correlate of HIV-1 control consisting of both innate and adaptive immune parameters best predicts viral load by multivariable analysis in HIV-1 infected viremic controllers and chronically-infected non-controllers. PLoS One 9:e103209
Tomescu, C; Abdulhaqq, S; Montaner, L J (2011) Evidence for the innate immune response as a correlate of protection in human immunodeficiency virus (HIV)-1 highly exposed seronegative subjects (HESN). Clin Exp Immunol 164:158-69
Ye, Li; Wang, Xu; Metzger, David S et al. (2010) Upregulation of SOCS-3 and PIAS-3 impairs IL-12-mediated interferon-gamma response in CD56 T cells in HCV-infected heroin users. PLoS One 5:e9602
Tomescu, Costin; Duh, Fuh-Mei; Lanier, Michael A et al. (2010) Increased plasmacytoid dendritic cell maturation and natural killer cell activation in HIV-1 exposed, uninfected intravenous drug users. AIDS 24:2151-60

Showing the most recent 10 out of 11 publications